Skip to content
Screener

Biohaven BHVN Operating Cash Flow

Operating Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$10.69B+246%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$95.39M-48.5%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$41.46M-65.4%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-$132.39M-69.5%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-$44.11M-27.1%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$19.99M-75.5%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.17B+41.2%
Enterprise value$2.18B+31.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Biohaven’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001935979-26-000045
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Prepaid expenses and other current and non-current assets12,564(7,238)
Accounts payable(1,221)91
Accrued expenses and other current and non-current liabilities(64,414)2,782
Net cash used in operating activities(149,918)(165,124)
Cash flows from investing activities:
Proceeds from maturities of marketable securities35,000210,000
Purchases of marketable securities(19,788)(44,660)
Purchases of property and equipment(461)

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Biohaven's operating cash flow?
Biohaven (BHVN) reported operating cash flow of -$149.92M in Q1 2026.
How has Biohaven's operating cash flow changed year-over-year?
Biohaven's operating cash flow increased by 9.2% year-over-year, from -$165.12M to -$149.92M.
What is the long-term trend for Biohaven's operating cash flow?
Over 3 years (2022 to 2025), Biohaven's operating cash flow has grown at a 27.0% compound annual growth rate (CAGR), from -$297.69M to -$609.44M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Biohaven's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude